CAPECITABINE FOR TARGETED ERADICATION OF ARISING CTDNA MOLECULAR RESIDUAL DISEASE IN ER+/HER2- NEGATIVE BREAST CANCER

Registry ID

CATER MRD

Source registry

HEALTH_CANADA

Status

Ongoing

Study type

INTERVENTIONAL

Sponsor

UNIVERSITY HEALTH NETWORK

Start date

2026-04-09

Last update

2025-08-06

Conditions

• ER+/HER2-BREAST CANCER

Related clinical trials

• A PHASE 3 RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED STUDY OF PALAZESTRANT WITH RIBOCICLIB VERSUS LETROZOLE WITH RIBOCICLIB FOR THE FIRST-LINE TREATMENT OF ER+, HER2–ADVANCED BREAST CANCER (OPERA-02)
• A PHASE I/II, OPEN-LABEL, MULTI-CENTER TRIAL OF [177LU]LU-NEOB IN COMBINATION WITH CAPECITABINE IN ADULT PATIENTS WITH GRPR+, ER+, HER2- METASTATIC BREAST CANCER AFTER PROGRESSION ON PREVIOUS ENDOCRINE THERAPY IN COMBINATION WITH A CDK4/6 INHIBITOR.
• A LIQUID-BIOPSY INFORMED PLATFORM TRIAL TO EVALUATE TREATMENT IN CDK4/6-INHIBITOR RESISTANT ER+/HER2- METASTATIC BREAST CANCER
• A PHASE III RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-9545 COMBINED WITH PALBOCICLIB COMPARED WITH LETROZOLE COMBINED WITH PALBOCICLIB IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER
• AN OPEN-LABEL, RANDOMIZED, MULTICENTER STUDY EVALUATING THE ACTIVITY OF LASOFOXIFENE RELATIVE TO FULVESTRANT FOR THE TREATMENT OF PRE- AND POSTMENOPAUSAL WOMEN WITH LOCALLY ADVANCED OR METASTATIC ER+/HER2- BREAST CANCER WITH AN ESR1 MUTATION

View on source registry